BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/22/2026 8:40:58 AM | Browse: 0 | Download: 0
 |
Received |
|
2026-02-02 02:48 |
|
Peer-Review Started |
|
2026-02-02 02:48 |
|
First Decision by Editorial Office Director |
|
2026-02-27 08:51 |
|
Return for Revision |
|
2026-02-27 08:51 |
|
Revised |
|
2026-03-11 20:28 |
|
Publication Fee Transferred |
|
2026-04-06 14:48 |
|
Second Decision by Editor |
|
2026-05-11 02:44 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-05-11 09:47 |
|
Articles in Press |
|
2026-05-11 09:47 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-06-09 14:38 |
|
Publish the Manuscript Online |
|
2026-06-22 08:40 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Prospective Study |
| Article Title |
Clinical study of Xianjun formula combined with standard western therapy in metastatic colorectal cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Lin-Feng Wang, Yu-Xing Sun, Jiang-Yu Bian and Tong Zhang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Xiyuan Hospital of China Academy of Chinese Medical Sciences |
No．XYZX0201-22 |
|
| Corresponding Author |
Tong Zhang, Associate Chief Physician, PhD, Department of Oncology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, No. 1, Xiyuan Playground, Haidian District, Beijing, China Academy of Chinese Medical Sciences Xiyuan Hospital, Beijing 100091, China. ashtray7654@126.com |
| Key Words |
Xianjun Formula; Metastatic colorectal cancer; Microsatellite stable; Late-line therapy; Overall survival; Integrative medicine |
| Core Tip |
Most metastatic colorectal cancer (mCRC) patients are microsatellite stable (MSS) and derive limited benefit from immune checkpoint inhibitor-based therapies, especially in late-line settings. This prospective, multicenter, single-arm clinical trial explores the feasibility and survival benefit of integrating Xianjun Formula, a traditional Chinese medicine compound, with standard Western therapies in refractory MSS mCRC. By targeting the tumor immune microenvironment, this study aims to provide preliminary clinical evidence supporting an integrative therapeutic strategy for patients lacking effective treatment options. |
| Publish Date |
2026-06-22 08:40 |
| Citation |
Wang LF, Sun YX, Bian JY, Zhang T. Clinical study of Xianjun formula combined with standard western therapy in metastatic colorectal cancer. World J Clin Oncol 2026; 17(6): 119607
|
| URL |
https://www.wjgnet.com/2218-4333/full/v17/i6/119607.htm |
| DOI |
https://doi.org/10.5306/wjco.119607 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
